News Wire ~ 3rd Party Press Release

186 POSTS 0 COMMENTS
EpiPen Malfunctions

FDA Warns of Possible Malfunctions for EpiPen, EpiPen Jr, and Mylan’s Generic Versions

Devices may potentially have delayed injection or be prevented from properly injecting.
#SnackSafelyAtHome

SnackSafely.com Launches #SnackSafelyAtHome Campaign to Help Consumers Find Allergy-Friendly Food Products Online

The program will be updated frequently as offerings are rolled out, new manufacturers join, and new, fully-vetted products are added to the platform.
Peanuts

Among Those Surveyed, One in Seven Peanut Allergic Adults First Developed Symptoms in Adulthood

Prevalence study examining peanut allergy characteristics in adults was scheduled to be presented at the 2020 AAAAI Annual Meeting.
AAAAI 2020 Cancelled

AAAAI Cancels 2020 Annual Meeting

The AAAAI is announcing today that it has canceled its 2020 Annual Meeting scheduled to take place March 13-16 in Philadelphia.
Mother Holding Infant

Study: Cesarean Birth Has Little Impact on Children Developing Allergies

The research found only a small link between cesarean delivery and asthma and no association between the delivery method and eczema or lung function.
Nose

ARS to Present Data from Intranasal Epinephrine (ARS-1) Studies at AAAAI 2020 Annual Meeting

Neffy™ (formally ARS-1) was fast-tracked by the FDA in 2019 as an intranasal alternative to epinephrine auto-injectors.
ZEGO Purity Panel

ZEGO Debuts New Purity Panel to Inform Consumers About Toxins in Food

ZEGO launches a new visual to bring transparency to undisclosed residues that can harm health.
Anxious Woman

Allergists Encourage Parents of Food Allergic Kids to Recognize Their Own Anxiety

"Children take cues from their parents, and their level of anxiety often reflects their parents’ level of anxiety..."
Viaskin-Patch

FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy...

Next step in the approval process for the therapy scheduled for May 15, 2020.
Alladapt

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy...

Company is developing therapy to target a number of food allergies simultaneously.